Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PharmaNet Development Group has entered into a partnership with Cancer Immunotherapy Trials Network (CITN) to help identify trials with CITN's immunotherapy agents which are used in cancer therapy.
Subscribe to our email newsletter
PharmaNet provides clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies.
PharmaNet has been conducting clinical studies for oncology products since 1996 and has an experienced team, including on-staff oncologists, dedicated to the development of cancer treatments.
The company develops cytotoxic chemotherapies, monoclonal antibodies, pathway inhibitors and therapeutic vaccines in most solid tumor types.
PharmaNet Oncology vice president, Clinical Research and General Manager Anthony Maida said clinical development of immunotherapies and cancer vaccines requires a special understanding of the mechanism of action and a different approach than traditional cancer therapies.
"We are working with clients to address the methodologies needed to evaluate efficacy and safety of this class of innovative therapeutics," Maida said.